Methylphenidate Hydrochloride
Product Images NDC 43598-441

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Methylphenidate Hydrochloride (NDC 43598-441). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Methylphenidate Hydrochloride Extended-Release Tablets, USP 18 mg by Dr.Reddys Laboratories Inc. The label indicates a 100-tablet quantity and includes storage information and a pharmacist instruction to dispense the accompanying medication guide to each patient. The label also contains barcodes, NDC number 43598-438-01, and the manufacturer's address details.*

FDA Label Image

Container2 (Container2)

Methylphenidate Hydrochloride Extended-Release Tablets, USP 27 mg, manufactured by Dr.Reddys Laboratories Inc. The label indicates a package containing 100 tablets. It includes directions for pharmacists to dispense the accompanying Medication Guide with each patient.*

FDA Label Image

Container3 (Container3)

Methylphenidate Hydrochloride Extended-Release Tablets, USP 36 mg, shown on a label from Dr. Reddy's Laboratories Inc. The label indicates a package size of 100 tablets and includes usage and storage instructions, a barcode, and a note for pharmacists to dispense the accompanying Medication Guide to each patient.*

FDA Label Image

Container4 (Container4)

Methylphenidate Hydrochloride Extended-Release Tablets, USP 54 mg label from Dr. Reddys Laboratories Inc. The packaging specifies 100 tablets, includes directions for use, storage conditions, NDC 43598-441-01, and barcode information on the right side.*

FDA Label Image

Figure1 (Figure1)

A line graph showing mean plasma methylphenidate concentration (ng/mL) over time (hours) for two dosing regimens: Methylphenidate HCl extended-release tablets at 18 mg once daily and Methylphenidate 5 mg three times daily. The graph compares plasma levels across a 32-hour period.*

FDA Label Image

Figure2 (Figure2)

A bar chart comparing Maximum Symptoms on an Inattention/Overactivity Scale between Methylphenidate Hydrochloride Extended-Release Tablets once daily and Placebo across three studies. Black bars represent Methylphenidate Hydrochloride, white bars represent Placebo. Symptom scores for Methylphenidate Hydrochloride are lower than Placebo in all studies, with study sample sizes indicated below each group.*

FDA Label Image

Figure3 (Figure3)

A line graph comparing the Combined Attention Subscale scores over 12 hours post initial dose between Methylphenidate Hydrochloride Extended-Release Tablets once daily and placebo. The y-axis indicates attention levels from less attentive to more attentive, and the x-axis indicates hours after the initial dose. Two lines represent the treatment and placebo groups with associated sample sizes noted.*

FDA Label Image

Structure (Structure)

Chemical structure of Methylphenidate Hydrochloride, showing its molecular arrangement including a phenyl ring, a methyl ester group, a piperidine ring, and a hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.